PMID: 6978834Jan 1, 1982Paper

Nonspecific inhibition of in vivo tumor growth by allo-sensitized lymphocytes - requirement of radio-sensitive T-lymphocytes

[Hokkaido igaku zasshi] The Hokkaido journal of medical science
F Sendo

Abstract

In previous papers we demonstrated with the Winn assay the WKA rat spleen cells sensitized to allogeneic tumor (AH-66 from Donryu strain) inhibited in vivo tumor growth of a syngeneic tumor (KMT-17) when early spleen cells (taken one week after the last immunization) were used. For the tumor inhibition by late spleen cells (2 weeks after the last immunization), further addition of inactivated homologous allogeneic cells was required. In the present study we examined with the Winn assay the nature of allo-sensitized spleen cells which nonspecifically inhibit in vivo growth of syngeneic tumors. Tumor inhibitory activity of early spleen cells was decreased by anti-rat T serum treatment. The same was true in tumor inhibition by late spleen cells stimulated with mitomycin-C treated AH-66 cells. Both of early and late spleen cells responsible for tumor inhibition are radio-sensitive, whereas KMT-17 sensitized T cells which specifically inhibited growth of homologous tumor cells belong to radio-resistant subpopulations.

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.